Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atiprimod Extension in Neuroendocrine Carcinoma
NCT00663429Phase 2Completed
- Sponsor
- Callisto Pharmaceuticals, Inc.
- Start
- Nov 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atiprimod in neuroendocrine carcinoma (NEC), sponsored by Callisto Pharmaceuticals, Inc. Primary endpoints: Reduction of symptoms (diarrhea, flushing and/or wheezing) at 1 year and Progression of neuroendocrine tumor(s) at 1 year. Started Nov 2007; status: completed.
02
Drugs
atiprimod
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT00663429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663429.